Route of infection, liver histology and response to interferon in patients with chronic hepatitis caused by genotype 4 HCV infection in a Western country

Remy, André‐Jean; Verdier, Eric; Perney, Pascal; Ducos, J; Blanc, F; Larrey, Dominique

doi:10.1016/s0168-8278(98)80192-x

Cited by 14 publications

(8 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Combination therapy with IFN and RBV produced SVRs ranging from 5% to 42%, whereas IFN‐alone arms ranged from 6% to 8%, which was comparable to earlier studies of IFN monotherapy (10–11%) . Thus, results for HCV‐4 were similar to, or worse than, results for HCV‐1.…”

Section: Hepatitis C Virus Genotypesupporting

confidence: 78%

Review article: the epidemiology and therapy of chronic hepatitis C genotypes 4, 5 and 6

Wantuck

Ahmed

Nguyen

2013

Aliment Pharmacol Ther

View full text Add to dashboard Cite

Summary Background The global burden of hepatitis C (HCV) infection is mostly found in Africa, the Middle East and Asia, where HCV genotypes 4, 5 and 6 are common. The literature on these genotypes is sparse and this synopsis will review characteristics of patients infected with these genotypes. Aim To review characteristics of patients infected with HCV genotypes 4, 5 and 6. Methods PubMed search for ‘hepatitis C’ AND ‘genotype 4’, ‘hepatitis C’ AND ‘genotype 5’, and ‘hepatitis C’ AND ‘genotype 6’ was conducted and relevant articles were reviewed. Results Intravenous drug use is generally responsible for HCV genotype 4 infection in developed countries, but unsafe medical practices cause most cases of HCV genotypes 4, 5 and 6 in endemic countries. The sustained virological response (SVR) rate for patients with HCV genotype 4 who receive pegylated interferon and ribavirin for 48 weeks ranges from 40% to 70% in various small studies. The SVR rate is in the 60–70% range for HCV genotype 5 and 70–80% range for HCV genotype 6 following 48 weeks with pegylated interferon and ribavirin. Preliminary data suggest that a shorter course of 24 weeks of pegylated interferon and ribavirin may be acceptable for HCV genotype 6, with an SVR rate of approximately 70%. Conclusions The current standard‐of‐care therapy for HCV genotypes 4, 5 and 6 is pegylated interferon and ribavirin for 48 weeks. A shorter course with 24 weeks of therapy may be considered for patients with genotype 6. Newer and much more effective therapies may be forthcoming in the next few years.

show abstract

Section: Hepatitis C Virus Genotypesupporting

confidence: 78%

Review article: the epidemiology and therapy of chronic hepatitis C genotypes 4, 5 and 6

Wantuck

Ahmed

Nguyen

2013

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

“…Genotype 4 is also the predominant HCV genotype in Saudi Arabia, comprising 50-75% of infections [Shobokshi et al, 1999]. The prevalence of genotype 4 in Europe generally does not exceed 5% [Nguyen and Keeffe, 2005], with a rate of 3.8% in southern Italy [Matera et al, 2002], 3.6% in Germany [Schroter et al, 2002], and 2.6% in France [Remy et al, 1998]. One of the highest rates, 9.4%, was reported in Galicia, Spain, but the main route of infection in that population was intravenous drug use [Martinez et al, 2005].…”

Section: Discussionmentioning

confidence: 99%

High prevalence of genotype 4 among hepatitis C virus‐infected intravenous drug users in North‐Eastern Poland

Chlabicz¹,

Flisiak²,

Kowalczuk³

et al. 2008

Journal of Medical Virology

View full text Add to dashboard Cite

The aim of this study was to describe the distribution of hepatitis C genotypes among intravenous drug users in north-eastern Poland. The study group included intravenous drug users recruited at a drug treatment center and a clinic for HIV-infected patients. HCV infection was confirmed by qualitative nested RT-PCR to test for the presence of HCV RNA. Genotypes were determined by 5'UTR sequencing and comparing the results with known genotype sequences. Among 111 HCV-infected and HCV-RNA-positive intravenous drug users, the most prevalent genotypes were 1 (38.7%), 3 (37.8%), and 4 (23.4%). Most infections with genotype 4 (88.5%) were found among HCV-HIV-coinfected drug users. The study demonstrated a high prevalence of genotype 4 (23.4%) among HCV-infected Polish drug users.

show abstract

“…In Calabria, Southern Italy, initial studies from 1996 found no evidence of HCV4, 19 but subsequently the prevalence of this genotype rose to 4.7% in the most recent studies 20 . More typical of the generally low prevalence of HCV4 in Europe is a recent French study that reported that among 1000 patients with HCV infection tested over a period of 3 years, 2.6% were infected with HCV4 21 . Most HCV4 patients in this study injected drugs.…”

Section: Epidemiologymentioning

confidence: 48%

“…In contrast, most studies from Europe suggest that the predominant route of HCV4 transmission there is intravenous drug use 18,21 . Zylberberg et al .…”

Section: Epidemiologymentioning

confidence: 97%

See 1 more Smart Citation

Management of hepatitis C virus genotype 4

Abdo

Lee

2004

J of Gastro and Hepatol

View full text Add to dashboard Cite

Hepatitis C virus (HCV) genotype 4 is predominantly found in the Middle East and North Africa. Because most of the large randomized controlled trials of antiviral therapy for chronic hepatitis C were conducted in North America and Europe, little is known about management of patients with this particular genotype. Based on the available data, sustained virological response rates to interferon-based therapies appear to be intermediate between the relatively resistant HCV genotype 1 and the readily responsive genotypes 2 and 3. Several large prospective studies of pegylated interferon plus ribavirin combination therapy, the current gold-standard treatment, have recently been completed and will be reviewed.

show abstract

Route of infection, liver histology and response to interferon in patients with chronic hepatitis caused by genotype 4 HCV infection in a Western country

Cited by 14 publications

References 5 publications

Review article: the epidemiology and therapy of chronic hepatitis C genotypes 4, 5 and 6

Review article: the epidemiology and therapy of chronic hepatitis C genotypes 4, 5 and 6

High prevalence of genotype 4 among hepatitis C virus‐infected intravenous drug users in North‐Eastern Poland

Management of hepatitis C virus genotype 4

Contact Info

Product

Resources

About